A report from EP Vantage forecasts that the combined sales of 34 drugs expected to be approved in the U.S. this year could reach a record $18.7 billion by 2018, up 14% from the estimated five-year revenue of 43 drugs cleared last year. If approved before the year ends, Gilead Sciences' hepatitis C drug sofosbuvir will be the top revenue-generating drug with expected sales of $3 billion by 2018, followed by Biogen Idec's Tecfidera with $2.9 billion in potential sales.

Related Summaries